ON123300, a multi-kinase inhibitor with high specificity for CDK4/CDK6 and NUAK1, showed a strong anti-tumorigenic effect on breast cancer, glioblastoma, lymphoma, and multiple myeloma and reduced Akt phosphorylation [48–51]. This evidence concerns the gene CDK4 and breast carcinoma.